WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company’s President and CEO, Tod Woolf, Ph.D., will deliver a session keynote presentation at IBC’s Oligonucleotide Therapeutics - From Concept to Creation Conference, which is part of Drug Discovery and Development Week, taking place August 3-6, 2009 in Boston, MA.
